We came across a bullish thesis on Harrow, Inc. on 1035 Capital Management’s Substack. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.'s share was trading at $34.37 as of July 15th. HROW’s trailing P/E was 9.64 according to Yahoo Finance.
[caption id="attachment_1207528" align="aligncenter" width="768"]Harrow (HROW) is executing a focused pharmaceutical rollup strategy within ophthalmology, targeting branded drugs with limited competition and integrating...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.